CA2855719C - Apoaequorin for reducing neuronal injury due to ischemia - Google Patents

Apoaequorin for reducing neuronal injury due to ischemia Download PDF

Info

Publication number
CA2855719C
CA2855719C CA2855719A CA2855719A CA2855719C CA 2855719 C CA2855719 C CA 2855719C CA 2855719 A CA2855719 A CA 2855719A CA 2855719 A CA2855719 A CA 2855719A CA 2855719 C CA2855719 C CA 2855719C
Authority
CA
Canada
Prior art keywords
apoaequorin
injury due
neuronal injury
ischemia
neurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2855719A
Other languages
English (en)
French (fr)
Other versions
CA2855719A1 (en
Inventor
Mark Y. Underwood
James R. Moyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quincy Bioscience LLC
Original Assignee
Quincy Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience LLC filed Critical Quincy Bioscience LLC
Publication of CA2855719A1 publication Critical patent/CA2855719A1/en
Application granted granted Critical
Publication of CA2855719C publication Critical patent/CA2855719C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2855719A 2011-11-15 2012-11-15 Apoaequorin for reducing neuronal injury due to ischemia Active CA2855719C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559816P 2011-11-15 2011-11-15
US61/559,816 2011-11-15
PCT/US2012/065291 WO2013074798A1 (en) 2011-11-15 2012-11-15 Apoaequorin for reducing neuronal injury due to ischemia

Publications (2)

Publication Number Publication Date
CA2855719A1 CA2855719A1 (en) 2013-05-23
CA2855719C true CA2855719C (en) 2021-10-26

Family

ID=47295186

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2855719A Active CA2855719C (en) 2011-11-15 2012-11-15 Apoaequorin for reducing neuronal injury due to ischemia

Country Status (23)

Country Link
US (1) US20140294874A1 (2)
EP (1) EP2780027B1 (2)
JP (1) JP6181061B2 (2)
KR (1) KR102009932B1 (2)
CN (1) CN104244966B (2)
AU (1) AU2012340446B2 (2)
BR (1) BR112014011630A2 (2)
CA (1) CA2855719C (2)
CY (1) CY1119300T1 (2)
DK (1) DK2780027T3 (2)
ES (1) ES2643392T3 (2)
HR (1) HRP20171532T1 (2)
HU (1) HUE035017T2 (2)
IL (1) IL232494B (2)
IN (1) IN2014CN04009A (2)
LT (1) LT2780027T (2)
MX (1) MX350259B (2)
PL (1) PL2780027T3 (2)
PT (1) PT2780027T (2)
SG (1) SG11201402364WA (2)
SI (1) SI2780027T1 (2)
WO (1) WO2013074798A1 (2)
ZA (1) ZA201403577B (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40959A (fr) * 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
KR20180001229A (ko) 2016-06-27 2018-01-04 삼성에스디아이 주식회사 이차 전지의 제조 방법 및 이를 이용한 이차 전지
HRP20241093T1 (hr) * 2016-09-23 2024-11-08 Quincy Bioscience Llc Sastavi koji sadrže apoaequorin i vitamin d i postupci uporabe istih
RU2642961C1 (ru) * 2017-02-21 2018-01-29 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемии головного мозга

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
SI2262525T1 (sl) * 2008-03-11 2013-03-29 Quincy Bioscience, Llc Apoaekuorin vsebujoči sestavki in postopki njihove uporabe
JP5919604B2 (ja) * 2008-08-08 2016-05-18 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗膵癌抗体
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin

Also Published As

Publication number Publication date
AU2012340446A1 (en) 2014-05-29
WO2013074798A1 (en) 2013-05-23
HUE035017T2 (en) 2018-03-28
PL2780027T3 (pl) 2017-11-30
DK2780027T3 (en) 2017-09-25
KR102009932B1 (ko) 2019-08-12
US20140294874A1 (en) 2014-10-02
JP6181061B2 (ja) 2017-08-16
BR112014011630A2 (pt) 2017-06-27
EP2780027B1 (en) 2017-07-19
HRP20171532T1 (hr) 2017-11-17
CA2855719A1 (en) 2013-05-23
ES2643392T3 (es) 2017-11-22
MX350259B (es) 2017-08-31
EP2780027A1 (en) 2014-09-24
SI2780027T1 (sl) 2017-11-30
SG11201402364WA (en) 2014-09-26
LT2780027T (lt) 2017-10-25
CN104244966A (zh) 2014-12-24
HK1202417A1 (en) 2015-10-02
IL232494B (en) 2019-03-31
KR20140097369A (ko) 2014-08-06
JP2014533692A (ja) 2014-12-15
CN104244966B (zh) 2019-01-11
IN2014CN04009A (2) 2015-10-23
CY1119300T1 (el) 2018-02-14
IL232494A0 (en) 2014-06-30
NZ624736A (en) 2016-05-27
MX2014005798A (es) 2014-05-30
AU2012340446B2 (en) 2017-08-31
PT2780027T (pt) 2017-10-04
ZA201403577B (en) 2015-07-29

Similar Documents

Publication Publication Date Title
WO2013142124A8 (en) Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
IN2014DN09434A (2)
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
WO2015042078A3 (en) Substituted aminopyrimidine compounds and methods of use
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2015051543A8 (en) Cancer treatment with combination of plinabulin and taxane
WO2012075492A3 (en) Carbocycle-substituted purine and 7-deazapurine compounds
PH12014500386A1 (en) Combination treatment for hepatitis c
HK1200716A1 (zh) 使用胞苷類似物的口服製劑治療癌症的方法
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
MX336347B (es) Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco.
WO2012112419A8 (en) Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate
WO2011117377A3 (en) Compositions comprising brimonidine for the treatment of erythema
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
CA2855719C (en) Apoaequorin for reducing neuronal injury due to ischemia
PE20151424A1 (es) Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales
MX2015011588A (es) Tratamiento de combinacion.
WO2009088992A3 (en) Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
WO2015082590A3 (en) Bis-mmf derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170613

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240916

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240916

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240916

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241101

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250611

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250916

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250922

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250922

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20251215